Releases

Current Releases

Amorfix announces third quarter 2010 results Biopharmaceutical Executive, Dr. Robert Gundel, joins Amorfix as Vice President, Research & Development Amorfix corporate update: AMF currently developing six products with first sales for amyloid products already achieved and first test of vCJD patient samples view complete archive

02/10/10 07:30 ET Quotes Delayed 20 minutes.